Source 1primary paper2026MED
Toolkit/lentivirus
lentivirus
Also known as: lentiviruses
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Usefulness & Problems
Why this is useful
Lentivirus is discussed as one of the delivery vehicles relevant to gene editing therapies for lipid metabolism and cardiovascular disease.; delivery of gene editing payloads; Lentivirus is described as a viral vector used for gene delivery in neurodegeneration-related therapeutic studies. The abstract places it within preclinical and clinical development.; gene delivery for neurodegeneration-related therapeutic strategies
Source:
Lentivirus is discussed as one of the delivery vehicles relevant to gene editing therapies for lipid metabolism and cardiovascular disease.
Source:
delivery of gene editing payloads
Source:
Lentivirus is described as a viral vector used for gene delivery in neurodegeneration-related therapeutic studies. The abstract places it within preclinical and clinical development.
Source:
gene delivery for neurodegeneration-related therapeutic strategies
Problem solved
It addresses the need to deliver gene editing systems.; provides a delivery vehicle for in vivo gene editing applications; It addresses the need to deliver therapeutic genes for neurodegenerative disease interventions.; delivering therapeutic genes in preclinical and clinical studies
Source:
It addresses the need to deliver gene editing systems.
Source:
provides a delivery vehicle for in vivo gene editing applications
Source:
It addresses the need to deliver therapeutic genes for neurodegenerative disease interventions.
Source:
delivering therapeutic genes in preclinical and clinical studies
Problem links
delivering therapeutic genes in preclinical and clinical studies
LiteratureIt addresses the need to deliver therapeutic genes for neurodegenerative disease interventions.
Source:
It addresses the need to deliver therapeutic genes for neurodegenerative disease interventions.
provides a delivery vehicle for in vivo gene editing applications
LiteratureIt addresses the need to deliver gene editing systems.
Source:
It addresses the need to deliver gene editing systems.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
No technique tags yet.
Target processes
editingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
Use requires a lentiviral gene delivery system and therapeutic payload. The abstract does not specify vector design or delivery details.; requires viral vector-based gene delivery
Validation breadth across biological contexts is still narrow. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Ranked Claims
The review discusses AAVs, LNPs, lentivirus, and virus-like particles as emerging delivery vehicles for gene editing therapies targeting lipid metabolism in cardiovascular disease.
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
AAVs and lentiviruses have been used for gene delivery in preclinical and clinical studies.
Adeno-associated viruses (AAVs) and lentiviruses have been used for gene delivery in preclinical and clinical studies
MSC-based paracrine support and transplantation of neurons derived from iPSCs are being evaluated as cellular therapies, particularly in Parkinson's disease and Alzheimer's disease.
Cellular therapies, including mesenchymal stem cell (MSC)-based paracrine support and transplantation of neurons derived from induced pluripotent stem cells (iPSCs), are being evaluated, particularly in PD and AD.
ASOs are under development to reduce expression of pathogenic proteins such as tau, α-synuclein, and mutant huntingtin.
ASOs are under development to reduce expression of pathogenic proteins such as tau, α-synuclein, and mutant huntingtin.
Current and developing therapeutic strategies for neurodegeneration include viral vector-based gene delivery, antisense oligonucleotide and RNA interference methods, stem cell transplantation, and genome editing technologies.
In this review, we describe current and developing therapeutic strategies that include viral vector-based gene delivery, antisense oligonucleotide (ASO) and RNA interference methods, stem cell transplantation, and genome editing technologies.
Approval Evidence
2 sources3 linked approval claimsfirst-pass slug lentivirus
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Source:
Adeno-associated viruses (AAVs) and lentiviruses have been used for gene delivery in preclinical and clinical studies.
Source:
delivery scopesupports
The review discusses AAVs, LNPs, lentivirus, and virus-like particles as emerging delivery vehicles for gene editing therapies targeting lipid metabolism in cardiovascular disease.
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Source:
application statementsupports
AAVs and lentiviruses have been used for gene delivery in preclinical and clinical studies.
Adeno-associated viruses (AAVs) and lentiviruses have been used for gene delivery in preclinical and clinical studies
Source:
scope statementsupports
Current and developing therapeutic strategies for neurodegeneration include viral vector-based gene delivery, antisense oligonucleotide and RNA interference methods, stem cell transplantation, and genome editing technologies.
In this review, we describe current and developing therapeutic strategies that include viral vector-based gene delivery, antisense oligonucleotide (ASO) and RNA interference methods, stem cell transplantation, and genome editing technologies.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.; The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Source:
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Source-backed strengths
explicitly described as used in both preclinical and clinical studies
Source:
explicitly described as used in both preclinical and clinical studies
Compared with AAV-based viral vectors
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.; The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Source:
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Compared with Adeno-associated virus
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Compared with antisense oligonucleotide
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Compared with anti-sense oligonucleotides
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Compared with antisense oligonucleotides
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Compared with lipid nanoparticles
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Compared with mRNA-lipid nanoparticles
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Compared with mRNA-loaded lipid nanoparticles
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Compared with stem cell transplantation
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentiviruses with AAVs and also mentions non-viral approaches including ASOs, RNA interference, stem cell transplantation, and genome editing.
Compared with virus-like particles
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Compared with virus-like particle vaccine platform
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly described as used in both preclinical and clinical studies.
Source:
The abstract contrasts lentivirus with AAVs, LNPs, and virus-like particles.
Ranked Citations
- 1.
- 2.